Nicotinamide Riboside

Summary

Nicotinamide Riboside (CHEMBL438497) is a phase-3 clinical-stage small-molecule geroprotector; indicated across 12 conditions including peripheral arterial disease and parkinson disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 12 conditions
• Clinical trials: 59
• Chemistry: 255.25 Da · C11H15N2O5+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL438497
Name	Nicotinamide Riboside
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	439924
ChEBI	CHEBI:15927
Molecular formula	C11H15N2O5+
Molecular weight	255.25
InChIKey	JLEBZPBDRKPWTD-TURQNECASA-O

SMILES: C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N

IUPAC name: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide

ChEBI definition: A pyridine nucleoside consisting of nicotinamide with a β-D-ribofuranosyl moiety at the 1-position.

Pharmacological roles (ChEBI): geroprotector.

Other ChEBI roles (chemical / environmental): human metabolite, Saccharomyces cerevisiae metabolite, mouse metabolite.

Also known as: Nicotinamide ribonucleoside, Nicotinamide riboside, Ribosylnicotinamide, NICOTINAMIDE RIBOSIDE

Patent coverage: 1,099 distinct patent families (2,136 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,020 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peripheral arterial disease	3	MONDO:0005386	EFO:0004265
Parkinson disease	3	MONDO:0005180	MONDO:0005180
peripheral neuropathy	2	MONDO:0005244	EFO:0003100
heart failure	2	MONDO:0005252	EFO:0003144
acute kidney injury	2	MONDO:0002492	HP:0001919
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
inborn mitochondrial myopathy	2	MONDO:0009637	Orphanet:206966
long COVID-19	2	MONDO:0100233	MONDO:0100233
systolic heart failure	1	MONDO:0006993	EFO:1001207

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 59.

Phase distribution

Phase	Trials
PHASE2	23
Not specified	20
PHASE1/PHASE2	4
EARLY_PHASE1	4
PHASE4	3
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05483465	PHASE4	RECRUITING	The Effect of NAD Supplementation on Brain Vascular Health in Aging
NCT06587945	PHASE4	RECRUITING	Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment
NCT03151707	PHASE4	TERMINATED	The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
NCT03568968	PHASE3	COMPLETED	A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson’s Disease
NCT03743636	PHASE3	COMPLETED	Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NCT03821623	PHASE2	RECRUITING	Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
NCT04112641	PHASE2	ACTIVE_NOT_RECRUITING	NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
NCT04870866	PHASE2	ACTIVE_NOT_RECRUITING	NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
NCT04913805	PHASE2	RECRUITING	Matching Perfusion and Metabolic Activity in HFpEF
NCT05194397	PHASE2	RECRUITING	Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
NCT05590468	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
NCT05732051	PHASE2	RECRUITING	Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
NCT06018467	PHASE2	ACTIVE_NOT_RECRUITING	Senolytics to Improve Osteoporosis Therapy
NCT06032923	PHASE1/PHASE2	RECRUITING	Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06162013	PHASE2	RECRUITING	The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism
NCT06567717	PHASE2	RECRUITING	Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
NCT06991712	PHASE2	RECRUITING	Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
NCT07579429	PHASE2	RECRUITING	Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
NCT02950441	PHASE2	UNKNOWN	Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype
NCT03423342	PHASE1/PHASE2	COMPLETED	Nicotinamide Riboside in Systolic Heart Failure
NCT03565328	PHASE2	TERMINATED	The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
NCT03579693	PHASE2	COMPLETED	Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
NCT03642990	PHASE2	TERMINATED	NR in Chemo-induced Peripheral Neuropathy
NCT03912220	PHASE2	COMPLETED	Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
NCT04040959	PHASE2	UNKNOWN	Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
NCT04110028	PHASE1/PHASE2	COMPLETED	Nicotinamide Riboside in Hospitalized Patients
NCT04342975	PHASE2	COMPLETED	Protection From Acute Kidney Injury (AKI) With Basis™ Treatment
NCT04407390	PHASE2	WITHDRAWN	Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly
NCT04818216	PHASE2	COMPLETED	Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
NCT05589766	PHASE2	COMPLETED	N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson’s Disease
NCT05593939	PHASE2	COMPLETED	Slow Age: Interventions to Slow Aging in Humans
NCT06534944	PHASE1/PHASE2	COMPLETED	NAD Supplementation and Vascular Health in PAD
NCT02689882	PHASE1	COMPLETED	Pharmacokinetic Study of Nicotinamide Riboside
NCT03635411	PHASE1	UNKNOWN	Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)
NCT06214468	PHASE1	COMPLETED	Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity
NCT04430517	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer’s Dementia
NCT04528004	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
NCT02300740	EARLY_PHASE1	COMPLETED	Pharmacokinetic Analysis of Nicotinamide Riboside
NCT03727646	EARLY_PHASE1	COMPLETED	Nicotinamide Riboside in LVAD Recipients
NCT04691986	Not specified	ACTIVE_NOT_RECRUITING	Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).